Plain English Breakdown
The official status indicates the governor vetoed the bill, but it is unclear if lawmakers overrode this veto based on the provided text alone.
AB-432 Menopause
This vetoed bill would remove the requirement to consider menopause courses, give doctors double credit for specific training between 2026 and 2032, and require health plans covering prescription drugs to cover perimenopause and menopause treatments.
What This Bill Does
- Removes the rule requiring medical boards to consider adding a course on menopausal mental or physical health.
- Gives qualifying physicians double continuing education credits for courses on perimenopause, menopause, and postmenopausal care from July 1, 2026, until July 1, 2032.
- Requires osteopathic physicians to receive the same double credit for completing similar coursework.
- Mandates that health insurance policies or service plan contracts covering outpatient prescription drugs include coverage for evaluation and treatment options for perimenopause and menopause symptoms if issued, amended, or renewed on or after January 1, 2026.
- Requires insurers to send annual clinical care recommendations about hormone therapy to primary care providers who treat individuals with these conditions.
Who It Names or Affects
- Physicians and surgeons licensed by the Medical Board of California
- Osteopathic physicians regulated by the Osteopathic Medical Board of California
- Health care service plans and health insurers that cover outpatient prescription drugs in California
Terms To Know
- Continuing education credit
- Points doctors earn by taking classes to keep their medical license active.
- Perimenopause
- The time period before menopause when hormone levels change and symptoms may start.
- Hormone therapy
- Medical treatment that uses hormones to manage symptoms of perimenopause or menopause.
Limits and Unknowns
- The governor vetoed this bill, so it did not become law unless lawmakers later overrode the veto.
- Coverage requirements apply only to plans covering outpatient prescription drugs and include unspecified exceptions.
- No state reimbursement is required for costs mandated by this act.